PE Tech Report


Like this article?

Sign up to our free newsletter

Neurofenix raises $7m in Series A round led by AlbionVC

Neurofenix, a neurological rehabilitation platform that uses sensor technology to improve patient recovery outcomes, has raised $7 million in Series A funding led by AlbionVC, with additional participation by HTH, InHealth Ventures, and existing investors.

The funding will enable Neurofenix to build out its product line and invest in US expansion, including funding US clinical trials. 

Founded in 2016 by Imperial graduates and Entrepreneur First alumni Guillem Singla Buxarrais (CEO) and Dimitrios Athanasiou (CTO), Neurofenix aims to revolutionise how neurological rehabilitation is delivered to drive better outcomes and recovery for patients. 

Neurofenix’s rehab programme currently focuses on arm and hand therapy through its NeuroBall device. 

Buxarrais and Athanasiou have brought together a team of 15 with pharmaceutical, clinical and healthcare commercial experience and are building out an advisory board which includes chairwoman Shirin Dehghan (operating partner at scale-up investor Frog Capital) and non-exec director Dr. Charles Carignan (former CMO of biomedical firm Boston Scientific). This Series A funding of $7m is in addition to an undisclosed amount of seed funding.

Like this article? Sign up to our free newsletter